Abstract:Abstract Introduction Psychiatric comorbidities are common in patients with excessive daytime sleepiness (EDS) from narcolepsy or obstructive sleep apnea (OSA). Real-world efficacy and safety data of wake promoting agents in these populations is limited. Solriamfetol (Sunosi®), a dopamine/norepinephrine reuptake inhibitor that activates TAAR1 and 5HT1A receptors, is approved to treat EDS associated with narcolepsy or OSA. Solriamfetol clinical trials excluded and the prescribing information caution against use in patients with severe psychiatric comorbidities, so limited data exists for this population. Here we describe real world use of solriamfetol in German patients with narcolepsy or OSA who self-reported depression/anxiety (yes/no response) at baseline. Methods We performed a retrospective chart review (SURWEY) using data from German physicians who prescribed solriamfetol to patients with EDS associated with narcolepsy or OSA and at a stable dose for ≥6 weeks. Comorbidities, including anxiety/depression, were documented with background information at baseline. Results Of the 154 patients, n=48 (31.2%) reported anxiety and/or depression (OSA, n=23/83 [27.7%], narcolepsy, n=25/71 [35.2%]). Most patients (≥85%) reported no additional psychiatric, neurological, or sleep disorder. Regardless of primary etiology, baseline mean±SD Epworth Sleepiness Scale (ESS) scores were generally similar in patients with (OSA, 16.0±2.8; narcolepsy, 17.9±3.6) and without (OSA, 16.0±3.3; narcolepsy, 17.5±2.9) anxiety/depression. Overall, mean±SD decreases in ESS scores were 4.6±3.2 and 5.2±3.6 with and without anxiety/depression, respectively; and similar in OSA (5.2±3.1 vs 5.5±3.9), narcolepsy (3.9±3.2 vs 4.9±3.3). Ninety percent of patients achieved ≥2-point reduction in ESS scores from baseline and patients (≥89%) and physicians (≥91%) reported improvement in EDS with solriamfetol, which were both similar across primary etiologies and anxiety/depression presence. Anxiety/depression data was not collected at follow-up. Common adverse events were headache, insomnia, and decreased appetite, which generally occurred at similar rates regardless of reported anxiety/depression. Conclusion These real-world data describe solriamfetol treatment outcomes in narcolepsy or OSA patients who did and did not self-report anxiety/depression. Regardless of anxiety/depression, ESS scores improved, and most patients and physicians reported improved EDS. Our findings are consistent with clinical trial results and suggest that solriamfetol is effective in managing EDS symptoms in this population regardless of common psychiatric comorbidities. Support (if any) Axsome Therapeutics, Jazz Pharmaceuticals, Pharmanovia

0649 Samelisant Improves the Symptoms of Excessive Daytime Sleepiness in Narcolepsy: Results from a Phase-2 Study

1021 Samelisant: Clinician and Patient Global Impression from a Double-Blind, Phase-2 Study in Patients with Narcolepsy

Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy

Efficacy of Melatonin for Prolonged Disorders of Consciousness: a Double-Blind, Randomized Clinical Trial

Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy

0637 Composite Response with Once-Nightly Sodium Oxybate: Symptom Improvement in Participants with Narcolepsy Type 1

0640 Magnitude of Improvement in Excessive Daytime Sleepiness with the Once-at-Bedtime Oxybate for Narcolepsy

1215 Adjunctive Use of Solriamfetol in Pediatric Excessive Daytime Sleepiness: A Single Center Experience

1024 SURWEY: Treatment of Excessive Daytime Sleepiness with Solriamfetol: Initiation, Titration, and Outcomes

0646 Efficacy Outcomes Among Male and Female Participant Subgroups: A Post Hoc Analysis from REST-ON

Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary

0650 Safety and Efficacy of KP1077 in a Phase 2, Double-Blind, Randomized Trial in Patients with Idiopathic Hypersomnia

Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial

Evaluating pharmacological treatments for excessive daytime sleepiness in obstructive sleep apnea: A comprehensive network meta-analysis and systematic review

0970 Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or Depression

Antidepressants for the Treatment of Narcolepsy: A Prospective Study of 148 Patients in Northern China

0630 Efficacy of Sodium Oxybate in Adults with Idiopathic Hypersomnia : A Randomized Placebo-controlled Trial

Long-term follow-up on the effects of sodium oxybate on daytime sleepiness and sleep architecture in patients with narcolepsy type 1

Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea

Improvement in sleep latency with extended-release once-nightly sodium oxybate for the treatment of adults with narcolepsy: Analysis from the phase 3 REST-ON clinical trial

Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications